Emergent Biosolutions EBS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.8M— | —— | $51.2M+527% | -$12M-118% | $68M+317% | ||
| $23.5M0.0% | $23.5M+0.4% | $23.4M-0.4% | $23.5M-7.5% | $25.4M-2.3% | ||
| $1.9M-64.2% | $5.3M+10.4% | $4.8M+4.3% | $4.6M+207% | $1.5M-65.1% | ||
| -$4.5M— | —— | -$10.2M— | —— | $18.6M+4,750% | ||
| $1.8M-30.8% | $2.6M+4.0% | $2.5M+4.2% | $2.4M+4.3% | $2.3M+4.5% | ||
| -$800K+20.0% | -$1M+54.5% | -$2.2M-120% | -$1M-233% | -$300K— | ||
| $38.9M+175% | -$51.9M-172% | $71.6M+160% | -$118.5M-262% | $73.3M-4.9% | ||
| -$15.8M— | —— | $17.6M-28.7% | $24.7M+1,023% | $2.2M— | ||
| -$14.4M— | —— | -$4M+61.5% | -$10.4M-92.6% | -$5.4M+47.1% | ||
| -$1.8M— | —— | —— | -$21.1M-193% | -$7.2M— | ||
| $500K— | —— | —— | -$19.7M-107% | -$9.5M+59.7% | ||
| $3.9M+143% | -$9.1M— | —— | —— | $11.3M+535% | ||
| $3.2M-22.0% | $4.1M+242% | $1.2M+500% | $200K+167% | -$300K+80.0% | ||
| $4.6M+173% | -$6.3M-202% | $6.2M— | —— | -$8.4M— | ||
| -$33.8M-144% | $77.7M— | $0-100% | $106.4M+1,050% | -$11.2M— | ||
| $2.4M-38.5% | $3.9M+14.7% | $3.4M+17.2% | $2.9M-19.4% | $3.6M+112% | ||
| $0— | —— | —— | $100K-99.7% | $38.1M+12,600% | ||
| -$2.4M— | —— | —— | $17.2M-71.1% | $59.5M+108% | ||
| $9M-1.1% | $9.1M+2.2% | $8.9M+29.0% | $6.9M— | $0— | ||
| $400K+140% | -$1M-600% | $200K-75.0% | $800K— | $0— | ||
| $2.8M+600% | $400K+33.3% | $300K+50.0% | $200K-60.0% | $500K+66.7% | ||
| -$11.4M+90.0% | -$113.9M-616% | -$15.9M-148% | -$6.4M-1,500% | -$400K— | ||
| $0— | —— | —— | $1M+243% | -$700K— | ||
| -$47.6M— | —— | —— | $118.2M+150% | $47.2M+193% | ||
| $13.1M+63.7% | $8M-52.7% | $16.9M+109% | $8.1M-51.5% | $16.7M+104% | ||
| $5.3M-57.6% | $12.5M+14.7% | $10.9M+419% | $2.1M-85.5% | $14.5M— | ||
| $1.8M-30.8% | $2.6M+4.0% | $2.5M+4.2% | $2.4M+4.3% | $2.3M+4.5% | ||
| -$800K+20.0% | -$1M+54.5% | -$2.2M-120% | -$1M-233% | -$300K— | ||
| -$20.2M— | —— | —— | —— | -$32.2M-288% | ||
| $4.6M+173% | -$6.3M-202% | $6.2M— | —— | -$8.4M— | ||
| $400K-50.0% | $800K+14.3% | $700K-12.5% | $800K0.0% | $800K-27.3% | ||
| $500K— | —— | —— | -$19.7M-107% | -$9.5M+59.7% | ||
| $3.9M+143% | -$9.1M— | —— | —— | $11.3M+535% | ||
| $0— | —— | —— | -$20M+33.3% | -$30M0.0% | ||
| $0— | —— | —— | —— | $5M— | ||
| $0— | —— | —— | $100K-99.7% | $38.1M+12,600% | ||
| —— | $950K0.0% | $950K0.0% | $950K0.0% | $950K— | ||
| $0— | $0+100% | -$800K-214% | $700K+600% | $100K-87.5% | ||
| $1M— | —— | —— | $700K-53.3% | $1.5M+400% | ||
| -$8.4M-215% | $7.3M— | —— | —— | -$9.5M-532% | ||
| $3.2M-22.0% | $4.1M+242% | $1.2M+500% | $200K+167% | -$300K+80.0% | ||
| -$36.2M-149% | $73.8M— | $0-100% | $103.5M+799% | -$14.8M— | ||
| -$36.2M-149% | $73.8M— | $0-100% | $103.5M+799% | -$14.8M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Emergent Biosolutions generate?
- Emergent Biosolutions (EBS) generated $150.3M in operating cash flow over the trailing twelve months.
- What is Emergent Biosolutions's free cash flow?
- After $12.6M of capital expenditures, Emergent Biosolutions's free cash flow was $141.1M over the trailing twelve months, up 310.0% year over year.
- Where does Emergent Biosolutions's cash flow data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
